Related Experiment Video
Updated: Dec 13, 2025

Multiplexed Fluorescent Microarray for Human Salivary Protein Analysis Using Polymer Microspheres and Fiber-optic Bundles
Published on: October 10, 2013
Multiplex Soluble Biomarker Analysis from Pleural Effusion
Joman Javadi1, Katalin Dobra1,2, Anders Hjerpe2
1Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Huddinge University Hospital, SE-14186 Stockholm, Sweden.
Abstract:
Malignant pleural mesothelioma (MPM) is a highly aggressive and therapy resistant pleural malignancy that is caused by asbestos exposure. MPM is associated with poor prognosis and a short patient survival. The survival time is strongly influenced by the subtype of the tumor. Dyspnea and accumulation of pleural effusion in the pleural cavity are common symptoms of MPM. The diagnostic distinction from other malignancies and reactive conditions is done using histopathology or cytopathology, always supported by immunohistochemistry, and sometimes also by analyses of soluble biomarkers in effusion supernatant. We evaluated the soluble angiogenesis related molecules as possible prognostic and diagnostic biomarkers for MPM by Luminex multiplex assay. Pleural effusion from 42 patients with malignant pleural mesothelioma (MPM), 36 patients with adenocarcinoma (AD) and 40 benign (BE) effusions were analyzed for 10 different analytes that, in previous studies, were associated with angiogenesis, consisting of Angiopoietin-1, HGF, MMP-7, Osteopontin, TIMP-1, Galectin, Mesothelin, NRG1-b1, Syndecan-1 (SDC-1) and VEGF by a Human Premixed Multi-Analyte Luminex kit. We found that shed SDC-1 and MMP-7 levels were significantly lower, whereas Mesothelin and Galectin-1 levels were significantly higher in malignant mesothelioma effusions, compared to adenocarcinoma. Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1, NRG1-β1, VEGF and TIMP-1 were significantly higher in malignant pleural mesothelioma effusions compared to benign samples. Moreover, there is a negative correlation between Mesothelin and shed SDC-1 and positive correlation between VEGF, Angiopoietin-1 and shed SDC-1 level in the pleural effusion from malignant cases. Shed SDC-1 and VEGF have a prognostic value in malignant mesothelioma patients. Collectively, our data suggest that MMP-7, shed SDC-1, Mesothelin and Galectin-1 can be diagnostic and VEGF and SDC-1 prognostic markers in MPM patients. Additionally, Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1 and TIMP-1 can be diagnostic for malignant cases.
Insights
Malignant pleural mesothelioma (MPM) diagnosis can be improved using specific biomarkers. Shed Syndecan-1 (SDC-1) and VEGF show prognostic value, while MMP-7, SDC-1, Mesothelin, and Galectin-1 aid in diagnosis.
Area of Science:
- Oncology
- Biomarker Discovery
- Pleural Diseases
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to asbestos exposure with poor prognosis.
- Current diagnostic methods for MPM include histopathology, cytopathology, and immunohistochemistry.
- Identifying reliable diagnostic and prognostic biomarkers for MPM remains a clinical challenge.
Purpose of the Study:
- To evaluate soluble angiogenesis-related molecules as potential diagnostic and prognostic biomarkers for MPM.
- To compare biomarker levels in MPM effusions against adenocarcinoma and benign effusions.
Main Methods:
- Analyzed 10 angiogenesis-related analytes (Angiopoietin-1, HGF, MMP-7, Osteopontin, TIMP-1, Galectin, Mesothelin, NRG1-b1, SDC-1, VEGF) in pleural effusions from 42 MPM, 36 adenocarcinoma, and 40 benign cases.
- Utilized Luminex multiplex assay for simultaneous quantification of multiple analytes.
Main Results:
- MMP-7 and shed SDC-1 were lower, while Mesothelin and Galectin-1 were higher in MPM vs. adenocarcinoma effusions.
- Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1, NRG1-β1, VEGF, and TIMP-1 were significantly higher in MPM vs. benign effusions.
- Shed SDC-1 and VEGF demonstrated prognostic value in MPM patients.
Conclusions:
- MMP-7, shed SDC-1, Mesothelin, and Galectin-1 show promise as diagnostic markers for MPM.
- VEGF and shed SDC-1 are potential prognostic markers for MPM.
- These biomarkers could improve the diagnostic accuracy and prognostic assessment of malignant pleural mesothelioma.

